Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefazolin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.86 |
| ▸ | BLM | P54132 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 9/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefazolin SCHEMBL11031717 | 1.00 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL3424683 | 1.00 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL16072809 | 1.00 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2841 | 1.00 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL3894722 | 1.00 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2842 | 1.00 | LMNA (1.00) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL2219475 | 0.99 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL40736 | 0.99 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL6364010 | 0.99 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 | |
| Cefazolin SCHEMBL29204288 | 0.99 | LMNA (0.98) | LMNAPTGS2SLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181330-B2 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2016-08-31 | — | — | EP | disclosed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | disclosed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | LMNA 1871/4885PTGS2 1099/4885SLC22A6 735/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | LMNA 541/4885PTGS2 906/4885SLC22A6 238/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | LMNA 1509/4885PTGS2 3521/4885SLC22A6 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.